Advertisement
Advertisement

RYTM

RYTM logo

Rhythm Pharmaceuticals, Inc. Common Stock

111.44
USD
Sponsored
+1.44
+1.31%
Aug 24, 16:00 UTC -4
Closed
exchange

After-Market

111.52

+0.08
+0.07%

Rhythm Pharmaceuticals, Inc. Common Stock Profile

About

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

Info & Links

CEO

David P. Meeker

Headquarters

222 BERKELEY STREET, 12TH FLOOR
BOSTON, MA 02116, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.rhythmtx.com

Auditor

Ernst & Young LLP

Share holders

13

Employees

414

Rhythm Pharmaceuticals, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

7.68B

Enterprise Value

7.61B

Enterprise Value/EBITDA(ttm)

-38.15

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

31.42

Price to Book(mrq)

73.20

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

89.11%

Operating Margin(ttm)

-85.59%

Profit Margin(ttm)

-89.05%

Return on Equity(ttm)

-159.87%

Return on Invested Capital(ttm)

-81.59%

Return on Assets(ttm)

-44.00%

Income Statement

Revenue(ttm)

239.92M

Revenue Per Share(ttm)

3.48

Gross Profit(ttm)

213.53M

EBITDA(ttm)3

-199.55M

Net Income Available to Common(ttm)

-210.22M

Diluted EPS(ttm)

-3.11

Share Statistics

Beta (5Y Monthly)

1.92

52-Week Change

7.91%

S&P 500 52-Week Change

18.66%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

68.85M

Dividend Yield

0.00%

Float4

64.49M

% Held by Insiders

5.90%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

330.90M

Total Cash Per Share(mrq)

4.81

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.45%

Quick Ratio(mrq)

3.20%

Book Value Per Share(mrq)

3.16

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.78

Free Cash Flow(ytd)

-53.34M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement